Evidence map›Paper›PMID 38795213›Full record

ArticleAnalytical and bioanalytical chemistry2024

Analytical control of imatinib in bioanalytical samples using graphene quantum dots sensing.

María A García-Trejo, Gregorio Castañeda, Ángel Ríos

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

María A García-TrejoDepartment of Analytical Chemistry and Food Technology, Faculty of Chemical Sciences and Technologies, University of Castilla-La Mancha, Campus Universitario, 13071, Ciudad Real, Spain.
Gregorio CastañedaDepartment of Analytical Chemistry and Food Technology, Faculty of Chemical Sciences and Technologies, University of Castilla-La Mancha, Campus Universitario, 13071, Ciudad Real, Spain.
Ángel RíosDepartment of Analytical Chemistry and Food Technology, Faculty of Chemical Sciences and Technologies, University of Castilla-La Mancha, Campus Universitario, 13071, Ciudad Real, Spain. angel.rios@uclm.es.ORCID http://orcid.org/0000-0003-1728-3097

Funding

Junta de Comunidades de Castilla - La Mancha SBPLY/21/180501/000188Junta de Comunidades de Castilla - La Mancha SBPLY/23/180225/000153Ministerio de Ciencia e Innovación PID2022-138761NB-I00University of Castilla - La Mancha 2022-GRIN-34376
6 · The paper itself

Abstract

An analytical method for the determination of imatinib (IMA, the primary treatment for chronic myeloid leukemia), based on the fluorescence properties of graphene quantum dots (GQDs), is reported in this work. The method is addressed to the analytical control of IMA in biological and pharmaceutical samples, due to the present interest in the control of the doses of this anticancer drug, as well as the therapeutic monitoring. The whole method involves the use of a solid-phase extraction (SPE) procedure, followed by an evaporation step, for the treatment of biological samples. For that, tC18 sorbent cartridges were used. After the sample treatment, the solution containing the analyte was mixed with an aqueous solution of GQDs at pH 7.2, and the fluorescent quenching of GQDs was measured. IMA was determined in the 10-250 µg L

Indexed as

Antineoplastic AgentsGraphiteImatinib MesylateLimit of DetectionQuantum DotsHumansReproducibility of ResultsSolid Phase ExtractionSpectrometry, FluorescenceAntineoplastic AgentsGraphiteImatinib MesylateBiological and pharmaceutical samplesFluorescent sensingGraphene quantum dotsImatinibSolid-phase extraction

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.